Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ZBIO

Zenas Biopharma Inc.

Sep 20 • 04:00PM ET

19.00

Dollar change +1.48
Percentage change 8.45	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	38.32M	Perf Week	4.68%
Market Cap	756.01M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	21.49M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	10.05%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-7.54	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	4.62	P/C	4.11	EPS next 5Y	-	ROE	-	52W Range	17.02 - 18.99	Perf YTD	4.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	0.05%	Beta	-
Dividend TTM	-	Quick Ratio	4.82	Sales past 5Y	-	Gross Margin	-	52W Low	11.63%	ATR (14)	1.12
Dividend Ex-Date	Dec 24, 2019	Current Ratio	4.82	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	5.46% -
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.27	Prev Close	17.52
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	507.43K	Price	19.00
SMA20	6.54%	SMA50	6.54%	SMA200	6.54%	Trades		Volume	135,254	Change	8.45%

Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc.

Upgrade your FINVIZ experience